2018 Viveve RF Vaginal Rejuvenation - Rock Bottom Lasers

Shop by Category

Laser Research


2018 Viveve RF Vaginal Rejuvenation

Product Question
Email Product

2018 Viveve RF Vaginal Rejuvenation; Excellent Operating & Cosmetic Condition; Reason for Selling: Downsizing; Includes: Handpiece, Footswitch & 90 Day Warranty. (Viveve Does Not Charge A Recertification Fee for Service or the Purchase of Consumables). (jp/vin)

Original price was: $85,000.00.Current price is: $14,975.00.

Out of stock

Laser Type:Radio Frequency, Monopolar Radio Frequency (CMRF)
Energy:90 J/cm2

The Viveve System provides sustained tissue tightening and strengthening by substantially heating the tissue at depth. The Viveve System’s patented, cryogen-cooled monopolar radiofrequency (CMRF) is unique in its ability to deliver volumetric heat (90 J/cm2) in order to stimulate robust neocollagenesis. This can be accomplished in just ONE session.

The Viveve System is indicated for use in general surgery for electrocoagulation and hemostasis in the USA.

Quick Facts
Single Session
Cryogen-Cooled Monopolar Radiofrequency
One 30-45 minute session
Safe and comfortable
Respectable and discreet

Women worldwide are increasingly demanding nonsurgical treatments. However, there are a limited number of safe and effective technologies specifically designed for women’s intimate health. Viveve provides clinically proven, innovative, nonsurgical treatments to improve women’s intimate health.

The Viveve System delivers a single-session treatment to generate collagen and restore tissue. The dual mode VIVEVE TREATMENT COOLS AND PROTECTS THE SURFACE WHILE HEATING THE DEEPER TISSUE. The Viveve Treatment is both safe and effective.

The Viveve Treatment is delivered via the patented, cryogen-cooled monopolar radiofrequency (CMRF) device that rebuilds natural collagen. CMRF technology allows for depth of penetration while maintaining patient comfort and safety.

Viveve has completed enrolling a clinical trial for sexual dysfunction under an IDE.

Viveve also has a Stress Urinary Incontinence IDE under FDA review.

Viveve received approval of an Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA) in March of 2018 to proceed with VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth.

* Shipping is included in the Continental USA only. Any shipment outside the lower 48 United States will be shipped at an extra cost. If you live outside this area, please contact us for a free shipping estimate.

Related Products

Join Our Mailing List

Subscribe to our email list to receive updates on our latest equipment listings.